Illumina and Labcorp have broadened their partnership to bring two FDA‑authorized oncology tests closer to patients. The collaboration will co‑commercialize Labcorp’s PGDx elio® plasma focus™ Dx liquid‑biopsy assay, the first and only kitted, pan‑solid‑tumor liquid‑biopsy test, alongside Illumina’s TruSight™ Oncology Comprehensive panel, the first FDA‑approved, distributable comprehensive genomic‑profiling IVD kit with pan‑cancer companion‑diagnostic claims.
The joint offering will enable hospitals and community health systems to access both tissue and liquid‑biopsy testing, improving diagnostic specificity and expanding eligibility for targeted therapies and clinical trials. By integrating these assays into Labcorp’s extensive network, Illumina can leverage its high‑throughput NovaSeq X instruments—over 890 units installed worldwide—to drive sequencing output growth of more than 30% year‑over‑year and increase consumables revenue from a broader customer base.
Illumina’s strategy to deepen clinical market penetration is reflected in its Q4 2025 results, where revenue of $1.16 billion was flat versus 2024 and adjusted EBITDA margin expanded to 23.7%, up 400 basis points. The company projects 2026 revenue of $4.5‑$4.6 billion and non‑GAAP diluted EPS of $5.05‑$5.20, driven by double‑digit growth in clinical consumables and the launch of new platforms such as TruPath Genome and spatial transcriptomics. The partnership with Labcorp aligns with this trajectory by expanding Illumina’s reach into liquid‑biopsy testing, a high‑growth segment of the precision‑oncology market projected to reach $201 billion by 2031.
CEO Jacob Thaysen said, "the momentum we have built going into 2026 gives me high confidence that the strategy we put in place in 2024 to return to long‑term growth is working." His statement underscores Illumina’s confidence in its execution and the expected impact of the expanded collaboration on its recurring consumables revenue stream.
The collaboration positions Illumina to counter competitive pressure from Roche’s AXELIOS 1 platform and other emerging short‑read sequencers. By offering a comprehensive, distributed testing solution that combines tissue and liquid‑biopsy assays, Illumina strengthens its market share in precision oncology and supports its goal of achieving higher operating margins through scale and operational leverage.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.